AC Lordi

Malvern’s AC Lordi, a boutique accounting and management consulting firm, has announced that Bill Dawson will lead the firm’s Risk and Compliance service line. Dawson will oversee offerings that include internal audit, Sarbanes-Oxley, systems audit and consulting, regulatory compliance, and enterprise risk management.

“Bill’s knowledge and experience across the broad range of our service offerings, especially in internal audit, will be instrumental in continuing to build one of the premiere management consulting practices in the Philadelphia region,” said AC Lordi CEO and Managing Principal Frank Lordi.

Since joining AC Lordi a year ago, Dawson has leveraged his strong background in accounting, reporting, audit, and business consulting to lead the internal audit practice while overseeing various client engagements.

Idera Pharmaceuticals

Exton’s Idera Pharmaceuticals – a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases – has reported positive financial and operational results for the third quarter of 2016.

Idera generated estimated net proceeds of $48.9 million, after deducting underwriters’ discounts and commissions and estimated offering expenses, from a public offering of common stock, including from the partial exercise by the underwriters of their option to purchase additional shares in the offering.

“The third quarter of 2016 was a very productive period for our team at Idera, and positions us well to close out the year very strong and carry that momentum into a catalyst-rich 2017,” said Vincent Milano, Idera’s CEO.

AMETEK

Berwyn’s AMETEK, a global leader in electronic instruments and electromechanical devices, has announced its financial results for the third quarter of 2016. The company reported sales of $945.0 million, down 5 percent from last year’s third quarter. Operating income was $201.1 million and operating margins were 21.3 percent in the quarter. Diluted earnings per share of $0.56 were down 14 percent from last year’s third quarter.

“I am pleased with our team’s performance, having delivered results that met our expectations in a challenging macro environment,” said David A. Zapico, AMETEK CEO. “Although prior year comparisons were impacted by weakness in oil and gas and metals markets, we are encouraged to see these markets begin to stabilize.”